Inhibiton Therapeutics Announces ICA-1 Compound Effective In In-Vitro Testing In Various Cancer Cell Lines

Inhibiton Therapeutics, Inc. (OTC/BB: IHBT) announced that its ICA-1 compound has been effective in laboratory in-vitro testing in various cancer cell lines. The present work performed under a Co-operative Research and Development Agreement (CRADA) with the Department of Veteran’s Affairs (VA) demonstrated that inhibition of the enzyme protein kinase C-iota is a promising means to prevent and treat certain cancers through development of a targeted therapy. [click link for full article]

More: continued here

Filed under: Cancer on December 6th, 2007